NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

ILT,

LP can find an alternative to Merck's BCG easily.

Here is the company from Germany that can supply BCG.
https://www.medac-group.com/focus-areas/urology

I suspect Merck must have BMS's PDUFA of SC Opdivo in their mind.

Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
Updated Prescription Drug User Fee Act (PDUFA) goal date of December 29, 2024

https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-Updated-Action-Date-by-the-U.S.-Food-and-Drug-Administration-for-Subcutaneous-Nivolumab-nivolumab-and-hyaluronidase/default.aspx